Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
Why now
Thesis: Early trial milestone, topline data in 2027
Catalyst to watch: Topline Phase 2a data in Q1 2027
Main risk: Early-stage trial, high failure probability
Why it matters
Phase 2a dosing is an early clinical milestone for a private-stage biotech; binary and distant.
Details
Initiation of patient dosing marks significant clinical development milestone for Nu-3 and Lakewood-Amedex Biotherapeutics' proprietary Bisphosphocin® antimicrobial platform Topline data expected in the first quarter of 2027 SARASOTA, Fla., Sept. 24, 2026 /PRNewswire/ -- Lakewood-Amedex...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-24 12:02 UTC